© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 2, 106-107,
January 20, 1999
© 1999 Oxford University Press
EDITORIALS |
aHIF: the Missing Link Between HIF-1 and VHL?
Affiliation of author: L. M. Neckers, Cell and Cancer Biology Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD.
Correspondence to: Leonard M. Neckers, Ph.D., National Institutes of Health, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850 (e-mail: len@helix.nih.gov).
Response to hypoxia at the cellular level is composed of two
components. Investigation of erythropoietin (EPO) gene regulation led
to the discovery several years ago of a novel, hypoxia-inducible
transcription factor, called hypoxia-inducible factor-1 (HIF-1), that
stimulates transcription of a number of cellular hypoxia-survival
genes, including EPO, vascular endothelial growth factor (VEGF),
certain glycolytic enzymes, and the glucose transport protein GLUT-1.
HIF-1 itself is heterodimeric, consisting of a constitutively expressed
subunit (HIF-1ß or ARNT [aryl hydrocarbon nuclear translocator
protein]) and a hypoxia-inducible subunit (HIF-1
). Hypoxia
appears to regulate HIF-1
not at the transcriptional level but by
post-transcriptional protein stabilization (1).
The second component of the cellular response to hypoxia involves the
stabilization of certain messenger RNAs (mRNAs), usually the very ones
whose genes are transcriptionally activated
REFERENCES